Innovative Injection Targets Hazardous Organ Fat with 12% Reduction in Clinical Study

Buzzline

A novel injection named CBL-514 has shown a 12.01% decrease in visceral fat, which is the harmful fat surrounding vital organs, during preliminary human trials. Two phase 2 studies utilized MRI imaging, revealing that four weeks post-treatment, the fat volume in the treated participants decreased by 12.01%, while the placebo group experienced a 5.68% increase. According to Dr. W. Timothy Garvey from the University of Alabama at Birmingham, the significance of weight reduction and loss of visceral fat outweighs mere aesthetic improvements. It is important to note that these trials are in the initial stages, participant numbers were not disclosed, and the findings do not establish definitive benefits. Consultation with a healthcare professional is recommended prior to any treatment. Disclosure: This video contains stock footage and content created or enhanced using AI-assisted tools.  ai-generated

Transcript

00:00a new belly fat injection is getting attention. An experimental drug called CBL-514 cut visceral

00:06fat, the dangerous fat around your organs, by 12% in early human trials. Two phase two trials

00:13used MRI scans. Four weeks after the last treatment, average fat volume fell 12.01%

00:19in the treated group and rose 568% in the placebo group. Visceral fat is linked to type 2 diabetes

00:26and heart problems, and laposuction cannot remove it. Dr. W. Timothy Garvey of the University of

00:32Alabama at Birmingham says weight loss matters more than looks. But these trials are early,

00:38sample sizes were not reported, and the drug is not approved. Talk to a doctor first.

00:43Disclosure. This video contains stock footage and content created or enhanced using AI-assisted tools.

Category

Transcript

Recommended